SHFI: A novel noninvasive predictive model for significant fibrosis in patients with chronic hepatitis B

4Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Background: This study aimed at creating a new predictive model of significant fibrosis in chronic hepatitis B using direct and indirect parameters and comparing this model with other noninvasive models for its validation in clinical settings. Methods: Patients (n = 81), according to the ISHAK score, were classified as mild and significant fibrosis. Serum matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-2, beta-nerve growth factor levels, and indirect parameters were analyzed. To evaluate the presence of significant hepatic fibrosis, well-known conventional models were also evaluated. The cut-off values of each model were determined using receiver operating characteristic curves to distinguish patients with mild and significant fibrosis. Results: Significant hepatic fibrosis index-1 was constructed using the following equation: (matrix metalloproteinase-2 × age × prothrombin time × direct bilirubin)/ (albumin _ platelet). The sensitivity and specificity for significant hepatic fibrosis index-1 were 73.3% and95.6%, respectively. Area under the curve of significant hepatic fibrosis index-1was0.895 (P< 0.001), whichwashigher than the other models. Due to limitations of matrix metalloproteinase-2, significant hepatic fibrosis index-2 was constructed using a formula without matrix metalloproteinase-2. However, there were no significant differences between significant hepatic fibrosis index-1 and significant hepatic fibrosis index-2 or other models, except for 3 models. Conclusions: Significant hepatic fibrosis index-1 employs anewmarker; matrix metalloproteinase-2 along with routine parameters had the best diagnostic performance for significant fibrosis in patients with chronic hepatitis B. Using significant hepatic fibrosis index-1 or even significant hepatic fibrosis index-2 might be an alternative approach in place of liver biopsy to predict significant fibrosis in chronic hepatitis B cohort.

Cite

CITATION STYLE

APA

Arslan, F. D., Karakoyun, I., Tatar, B., Pala, E. E., Yıldırım, M., Ulasoglu, C., … Basok, B. I. (2018). SHFI: A novel noninvasive predictive model for significant fibrosis in patients with chronic hepatitis B. Hepatitis Monthly, 18(2). https://doi.org/10.5812/hepatmon.63310

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free